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Abstract
Aims/hypothesis Ceramide lipids have a role in the development of insulin resistance, diabetes and risk of cardiovascular disease.
Here we investigated four ceramides and their ratios to find the best predictors of incident diabetes.
Methods A validated mass-spectrometric method was applied to measure Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/
24:0) and Cer(d18:1/24:1) from serum or plasma samples. These ceramides were analysed in a population-based risk factor
study (FINRISK 2002, n = 8045), in a cohort of participants undergoing elective coronary angiography for suspected
stable angina pectoris (Western Norway Coronary Angiography Cohort [WECAC], n = 3344) and in an intervention trial
investigating improved methods of lifestyle modification for individuals at high risk of the metabolic syndrome (Prevent
Metabolic Syndrome [PrevMetSyn], n = 371). Diabetes risk score models were developed to estimate the 10 year risk of
incident diabetes.
Results Analysis in FINRISK 2002 showed that the Cer(d18:1/18:0)/Cer(d18:1/16:0) ceramide ratio was predictive of incident
diabetes (HR per SD 2.23, 95% CI 2.05, 2.42), and remained significant after adjustment for several risk factors, including BMI,
fasting glucose and HbA1c (HR 1.34, 95% CI 1.14, 1.57). The finding was validated in the WECAC study (unadjusted HR 1.81,
95% CI 1.53, 2.14; adjusted HR 1.39, 95% CI 1.16, 1.66). In the intervention trial, the ceramide ratio and diabetes risk scores
significantly decreased in individuals who had 5% or more weight loss.
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Conclusions/interpretation The Cer(d18:1/18:0)/Cer(d18:1/16:0) ratio is an independent predictive biomarker for incident dia-
betes, and may be modulated by lifestyle intervention.
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Introduction
Type 2 diabetes is a serious progressive metabolic disorder in
which the body becomes resistant to insulin and gradually
loses the capacity to produce it in sufficient amounts.
Worldwide, an estimated 422 million adults were afflicted
by diabetes in 2014, and the global age-standardised preva-
lence has doubled since 1980, now being 8.5% in the adult
population [1]. Type 2 diabetes can lead to severe
complications, including kidney, retinal and neural damage,
and accelerated cardiovascular disease resulting in myocardial
infarctions or strokes [2].
According to WHO guidelines, type 2 diabetes is diag-
nosed if: (1) the fasting plasma glucose level is 7 mmol/l or
higher; (2) the 2 h plasma glucose level is 11.1 mmol/l or
higher during a glucose tolerance test; or (3) the HbA1c
level is 47.5 mmol/mol (6.5%) or higher [1]. Prediabetes
is an intermediate state of hyperglycaemia with glycaemic
variables above normal but below the type 2 diabetes
threshold; however, the exact diagnostic criteria of predia-
betes are not uniform across various international profes-
sional organisations [3]. Importantly, lifestyle interven-
tions affecting diet, weight management and physical ac-
tivity significantly decrease the risk of conversion from the
prediabetic state to type 2 diabetes [3]. Thus, identifying
individuals at greatest risk and motivating them to lifestyle
changes are highly important in the prevention of type 2
diabetes and its complications.
•
•
•
•
•
•
•
•
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Ceramides are sphingolipids that have a crucial role in the
development of type 2 diabetes and other cardiometabolic
disorders. Several studies have investigated the role and
mechanisms underlying the contribution of ceramides to the
development of insulin resistance in various tissues [4, 5].
Moreover, it was recently demonstrated in both mice and
humans that concentrations of plasma dihydroceramides, cer-
amide precursor molecules, are already elevated years before
the onset of type 2 diabetes [6]. We previously described the
value of three ceramides [Cer(d18:1/16:0), Cer(d18:1/18:0),
Cer(d18:1/24:1)] and their ratios to Cer(d18:1/24:0) in
predicting cardiovascular risk, especially cardiovascular
death, in both secondary and primary prevention cardiovascu-
lar studies [7, 8]. Prior results suggest that one of these
ceramides, Cer(d18:1/18:0), was also able to predict the risk
of future type 2 diabetes [6]. The aim of the present study was
to investigate how these cardiovascular disease-associated
ceramides predict incident type 2 diabetes and are modulated
by lifestyle intervention.
Methods
FINRISK 2002 study population The FINRISK survey has
been performed every 5 years since 1972 mainly to monitor
trends in cardiovascular risk factors in the Finnish population
[9]. The FINRISK 2002 study is a stratified random sample of
the population aged 25–74 years from specific geographical
areas of Finland. The survey included participants from North
Karelia and Northern Savo in eastern Finland, the Turku and
Loimaa regions in south-western Finland, the cities of
Helsinki and Vantaa in the capital region, the provinces of
Northern Ostrobothnia and Kainuu in north-western Finland
and the province of Lapland in northern Finland. Sampling
was stratified by sex, region and 10 year age groups so that
each stratum contained 250 participants. In North Karelia,
Lapland and the cities of Helsinki and Vantaa, the strata of
65–74-year-oldmen and womenwere also sampled, eachwith
250 participants. The original population sample was thus
13,500 (minus 64 who had died or moved away between
sampling and the survey); the overall participation rate was
65.5%, including a questionnaire and a health examination
during which blood samples were drawn. The study protocol
was approved by the Coordinating Ethics Committee of the
Helsinki and Uusimaa Hospital District and all participants
gave written informed consent.
Serum samples from 8121 participants were available for
the present study, and pregnant women (n = 46) as well as
those with missing clinical variables (n = 30) were excluded
from the data. This left 8045 participants, of whom 445 had
prevalent type 2 diabetes and 593 developed incident type 2
diabetes during the follow-up. The participants were advised
to fast for 4 h or longer and to avoid heavy meals earlier in the
day. Serum was separated and stored at −70°C. Some
analytes, such as conventional lipids, were measured immedi-
ately. The detailed methods have previously been described
[9]. The authors had full access to the data used in this study.
The participants were followed up until 31 December 2014,
i.e. for 13 years. Only participants who had permanently
moved abroad (<1%) before the disease event or 31
December 2014 were lost to follow-up. Prevalent diseases
were defined as those that had developed prior to or at the
baseline examination date, and incident events were those
occurring thereafter. Individuals with incident diabetes during
follow-up were identified by record linkage of the FINRISK
2002 data with the countrywide electronic health registers on
the basis of the personal ID-code, unique to every permanent
resident of Finland. Registers included the Causes-of-Death
Register, Hospi ta l Discharge Register and Drug
Reimbursement Registers. This procedure has previously
been described in detail [10].
All 45–74-year-old individuals were invited further to par-
ticipate in a 2 h glucose tolerance test. In addition, HbA1c was
measured in participants of all ages in North Karelia, the cap-
ital region and the Turku/Loimaa regions. Both fasting glu-
cose and HbA1c measurements were available for 2119 par-
ticipants; this population is referred to here as the FINRISK
2002 substudy.
Western Norway coronary angiography cohort study popula-
tion Citrate plasma samples were obtained from the Western
Norway Coronary Angiography Cohort (WECAC), which
consists of 5209 adults who underwent coronary angiography
at Haukeland University Hospital, Bergen, or Stavanger
University Hospital, Stavanger, in Norway between January
2000 and April 2004 [11]. The study was carried out accord-
ing to the Declaration of Helsinki and approved by the
Regional Committee for Medical and Health Research
Ethics and the Norwegian Data Inspectorate. The primary
aim of WECAC was to study various prognostic biomarkers
of cardiovascular endpoints. WECAC includes 3090 partici-
pants who were randomised to participate in the Western
Norway B vitamin Intervention Trial (WENBIT;
ClinicalTrials.gov number NCT00354081) to investigate the
effect of B vitamin supplementation on mortality and
cardiovascular events [12]. The trial did not find an effect of
treatment with folic acid/vitamin B12 or B6 on cardiovascular
events or total mortality [12].
Altogether, 4634 baseline samples were analysed, and only
participants examined because of suspected stable angina
pectoris were considered for the current investigation (n =
3927). Those individuals with missing ceramide or clinical
data were excluded (n = 69). Moreover, we excluded partici-
pants with any of the following: a self-reported diagnosis of
diabetes mellitus (type 1 or type 2) at baseline (n = 442),
fasting plasma glucose ≥7.0 mmol/l (n = 45) or non-fasting
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plasma glucose ≥11.1 mmol/l (n = 27). Using these criteria, a
total of 3344 eligible individuals were included in the final
analyses. Individuals with incident diabetes during the follow-
up were identified from the Norwegian prescription database,
hospital discharge diagnosis and WENBIT trial follow-up, as
previously described in detail [13]. Because information on
incident diabetes was collected through 31 December 2009,
i.e. before the HbA1c criterion was implemented in the diag-
nosis of diabetes [14], the diagnosis of type 2 diabetes was
based only on glucose levels. We performed additional anal-
yses after excluding participants with HbA1c ≥ 47.5mmol/mol
(6.5%) at baseline (n = 2352). The median follow-up time for
incident diabetes in the WECAC cohort was 7.6 years.
Prevent metabolic syndrome study The Prevent Metabolic
Syndrome (PrevMetSyn) trial is a population-based
randomised study that consists of either overweight or obese
individuals [15]. All procedures of the study comply with the
Declaration of Helsinki (World Medical Association 2013).
All study participants gave written informed consent, and
the study was approved by the Ethics Committee of the
Hospital District of Northern Ostrobothnia, Oulu, Finland (de-
cision number 29/2012). The study is registered at
ClinicalTrials.gov with the identifier NCT01959763.
The sample was collected using the address and informa-
tion system of the Finnish Population Register Center.
Invitation letters were sent to people aged 20–60 years living
in the city of Oulu. Eligibility criteria were: (1) a BMI of 27–
35 kg/m2; (2) access to the Internet; (3) no health-related re-
strictions for losing weight (such as pregnancy); and (4) no
other ongoing treatment for obesity. Volunteers were invited to
a screening visit at the enrolment site at the Oulu University
Hospital. After the screening, the participants were
randomised and started the lifestyle intervention; they
attended follow-up visits after the first and second years of
the intervention.
Blood samples were drawn during the screening and study
visits at the research laboratory of the Oulu University
Hospital. Blood pressure, waist circumference, height and
weight were also measured. All the procedures have been
described in detail and approved by the Ethics Committee of
the Hospital District of Northern Ostrobothnia, Oulu, Finland.
Samples from 375 participants were analysed, and four were
excluded due to missing ceramide or clinical data, leaving 371
individuals for the analyses.
Analysis of ceramides The analysis of ceramides from serum
samples has previously been described in detail [8, 16]. In
brief, ceramide quantification was performed using a validat-
ed high-throughput mass spectrometry approach [16]. Serum
or plasma samples (10 μl) were spiked with 2H (deuterium
[D])-labelled internal standards, D7-Cer(d18:1/16:0), D7-
Cer(d18:1/18:0), D7-Cer(d18:1/24:0) and D7-Cer(d18:1/
24:1), and extracted in isopropanol:ethyl acetate (8:2, vol./
vol.) using a Hamilton MICROLAB STAR robot (Hamilton
Robotics, Kista, Sweden). The levels of Cer(d18:1/16:0),
Cer(d18:1/18:0), Cer(d18:1/24:0) and Cer(d18:1/24:1) were
quantified on a QTRAP6500 (AB SCIEX, Concord, ON,
Canada) mass spectrometer equipped with an Eksigent 100-
XL ultra-HPLC system (AB SCIEX). The individual
ceramides were quantified in multiple-reaction-monitoring
mode. Quantification was assessed through calibration line
samples comprising of known amounts of synthetic
Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0) and
Cer(d18:1/24:1) and corresponding 2H-labelled standards.
The peak area ratios of each ceramide to its corresponding
2H-labelled form were calculated, plotted against the added
ceramide concentration and fitted by linear regression analy-
sis. Final ceramide concentrations were presented in μmol/l.
Statistical methods The baseline characteristics are described
using medians (interquartile range) for continuous variables,
and numbers (percentages) for categorical variables. Cox pro-
portional hazard regression analyses were used to determine
associations of the ceramide ratios with incident diabetes, after
excluding individuals with prevalent diabetes. Full models
were adjusted for the following risk factors: age, BMI,
HDL-cholesterol (HDL-C), C-reactive protein (CRP), current
smoking status, lipid-lowering treatment and systolic blood
pressure (in FINRISK, 15 mmHg was added for participants
on antihypertensive medication). In addition, WECAC was
adjusted by sex, and FINRISK 2002 by waist circumference,
eastern location in Finland, family history of diabetes (first-
degree relatives), physical activity (binary variable for physi-
cal activity during free time) and socioeconomic status, de-
fined as educational level (low, medium, high). Some models
were additionally adjusted for glucose and HbA1c. In
WECAC, the vitamin B intervention arms, alone or in com-
bination with the investigated ceramide ratio, did not show an
interaction with the development of diabetes in Cox regression
models, but the intervention arms were used as a stratifying
variable. In FINRISK 2002, the models were stratified by sex.
All continuous covariates, including baseline age and cer-
amide level, were loge-transformed, and their effects are
expressed per SD of the transformed variable. Individuals
were excluded from the analyses if data relating to any of
the variables was missing.
For prediction, Cox regression models were construct-
ed based on FINRISK 2002 to predict the 10 year abso-
lute risk of incident diabetes, using tenfold crossvalidation
to prevent overoptimism. The increase in C-statistic
resulting from the addition of the Cer(d18:1/18:0)/
Cer(d18:1/16:0) ratio into the model was evaluated using
the method of Antolini et al [17] for correlated C-statis-
tics. Calibration of the models was estimated using the
Hosmer–Lemeshow test. For validation, the regression
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coefficients from FINRISK 2002 were used to predict the
7 year risk in the WECAC study. In this validation, the
baseline hazard was recalibrated in the WECAC study.
The diabetes risk scores were derived directly from the
models developed in FINRISK 2002.
In the PrevMetSyn study, the data were log2-transformed
and paired t tests were performed to calculate the significance
of changes at 1 or 2 years relative to baseline. Software pack-
age R version 3.4.3 [18] was used for all statistical analyses. A
value of p < 0.05 was considered statistically significant, and
all tests were two-sided.
Results
Stearic acid (18:0) ceramide shows the strongest association
with incident diabetes Four ceramides, Cer(d18:1/16:0),
Cer(d18:1/18:0), Cer(d18:1/24:0) and Cer(d18:1/24:1), were
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Fig. 1 Cer(d18:1/18:0)/
Cer(d18:1/16:0) ratio in
individuals (a) without type 2
diabetes (T2D), or with incident
T2D or prevalent T2D, and (b) in
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Table 1 HRs for Cer(d18:1/
18:0) and its ratios with other
ceramides for incident diabetes in
the FINRISK 2002 study
Ceramide HR (95% CI)a p valuea HR (95% CI)b p valueb
Cer(d18:1/18:0)/Cer(d18:1/16:0) 2.23 (2.05, 2.42) <2.2 × 10−16 1.48 (1.34, 1.63) 5.6 × 10−15
Cer(d18:1/18:0) 1.95 (1.80, 2.12) <2.2 × 10−16 1.32 (1.20, 1.45) 1.7 × 10−8
Cer(d18:1/18:0)/Cer(d18:1/24:0) 1.72 (1.59, 1.87) <2.2 × 10−16 1.19 (1.09, 1.31) 2.4 × 10−4
Cer(d18:1/18:0)/Cer(d18:1/24:1) 1.66 (1.54, 1.80) <2.2 × 10−16 1.19 (1.09, 1.30) 1.1 × 10−4
FINRISK 2002 substudy
Cer(d18:1/18:0)/Cer(d18:1/16:0) 1.98 (1.74, 2.27) <2.2 × 10−16 1.34 (1.14, 1.57) 3.8 × 10−4
Cer(d18:1/18:0) 1.66 (1.45, 1.90) 1.7 × 10−13 1.27 (1.09, 1.48) 0.002
Cer(d18:1/18:0)/Cer(d18:1/24:0) 1.64 (1.43, 1.87) 3.6 × 10−13 1.25 (1.08, 1.46) 0.004
Cer(d18:1/18:0)/Cer(d18:1/24:1) 1.62 (1.42, 1.84) 1.1 × 10−12 1.15 (0.98, 1.34) 0.078
HRs are expressed per 1 SD
aUnadjusted models, stratified by sex
bModels stratified by sex and adjusted for age at baseline, BMI, waist circumference, eastern location in Finland,
HDL-C, CRP, systolic blood pressure (15 mmHg was added for participants on antihypertensive medication),
lipid-lowering treatment, current smoking, family history of diabetes, physical activity and educational level, and,
in the substudy, additionally for fasting glucose and HbA1c
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analysed in the FINRISK 2002 population study (n = 8045;
see electronic supplementary material [ESM] Table 1). In un-
adjusted Cox regression models, all ceramides and ceramide
ratios were significantly associated with future type 2 diabe-
tes, and several of these remained significant after adjusting
for other diabetes-associated variables (ESM Table 2).
However, in an analysis of the substudy with fasting glucose
and HbA1c data available (ESM Table 3), adjusting addition-
ally for these variables the highest significant HRs were ob-
served for Cer(d18:1/18:0) and Cer(d18:1/18:0)/Cer(d18:1/
24:0) (ESM Table 2).
Among the ceramides, Cer(d18:1/18:0)/Cer(d18:1/16:0) ratio
is the best predictor of incident diabetes As distinct
ceramides have specific roles in different cardiometabolic dis-
orders, ceramide ratios may appear to be better predictors than
individual ceramide concentrations [7]. To this end, we inves-
tigated the ratios of Cer(d18:1/18:0) to the other ceramides,
and observed that the most significant predictor in univariate
and multivariable analyses was the Cer(d18:1/18:0)/
Cer(d18:1/16:0) ratio (Table 1). The HR for this ceramide
ratio was more significant than for several traditional risk
markers including cholesterol measurements (total cholester-
ol, LDL-cholesterol and HDL-C), triacylglycerols (TGs),
CRP and systolic blood pressure, while glucose and HbA1c
were stronger predictors of incident type 2 diabetes, which is
expected as they form the diagnostic definition of the disease
(ESM Table 4).
The Cer(d18:1/18:0)/Cer(d18:1/16:0) ratio was elevated in
individuals with prevalent diabetes or with incident diabetes
compared with individuals who remained free of type 2 dia-
betes during the follow-up (Fig. 1a). Furthermore, this ratio
was elevated by lipid-lowering treatment (Fig. 1b). This ratio,
followed by Cer(d18:1/18:0), was the ceramide variable that
correlated most significantly with BMI, waist circumference,
insulin, glucose and HbA1c (Fig. 1c). Of note, Cer(d18:1/16:0)
was not statistically significantly associated to any of these
variables. There was no difference in the ratio between men
and women (p = 0.55).
Validation of the diabetes-associated ceramide ratio in indi-
viduals with suspected stable angina pectoris The predictive
value of the Cer(d18:1/18:0)/Cer(d18:1/16:0) ratio was vali-
dated in the WECAC study (n = 3344; ESM Table 5). In
WECAC as well, the Cer(d18:1/18:0)/Cer(d18:1/16:0) ratio
showed the strongest association with incident type 2 diabetes
(Table 2). The Cox regression results for other clinical mea-
surements were similar to those for the FINRISK 2002 study,
i.e. CRP was significant primarily in unadjusted models,
HDL-C and TGswere the only significant measurements from
the lipid panel, and glucose showed the highest univariate and
multivariable HRs (ESMTable 6). In addition to excluding the
participants with self-reported diabetes and high glucose
levels, we also analysed the WECAC study after excluding
all individuals with HbA1c ≥ 47.5 mmol/mol (6.5%) at base-
line. The results remained consistent, although the HRs de-
creased for all the investigated variables (Table 2, ESM
Table 6).
Prediction of incident diabetes and score Cox regression
models were constructed to predict the 10 year risk of incident
diabetes in the FINRISK 2002 study and validated in the
WECAC study for 7 year risk. For validation, regression coef-
ficients from the FINRISK 2002 study were used, but due to
the different nature and follow-up time of the study, baseline
hazard was recalibrated for the WECAC study. In addition to
Table 2 HRs of Cer(d18:1/18:0) and its ratios with other ceramides for incident diabetes in the WECAC study
Ceramide HR (95% CI)a p valuea HR (95% CI)b p valueb HR (95% CI)c p valuec
Cer(d18:1/18:0)/Cer(d18:1/16:0) 1.81 (1.53, 2.14) 2.4 × 10−12 1.51 (1.26, 1.81) 9.8 × 10−6 1.39 (1.16, 1.66) 3.7 × 10−4
Cer(d18:1/18:0) 1.53 (1.31, 1.79) 7.6 × 10−8 1.30 (1.09, 1.54) 0.003 1.19 (1.00, 1.42) 0.053
Cer(d18:1/18:0)/Cer(d18:1/24:0) 1.43 (1.22, 1.68) 1.2 × 10−5 1.19 (1.01, 1.42) 0.043 1.18 (0.99, 1.40) 0.060
Cer(d18:1/18:0)/Cer(d18:1/24:1) 1.30 (1.11, 1.52) 0.001 1.13 (0.95, 1.33) 0.172 1.05 (0.88, 1.24) 0.611
WECAC (HbA1c < 47.5 mmol/mol)
Cer(d18:1/18:0)/Cer(d18:1/16:0) 1.66 (1.34, 2.04) 2.3 × 10−6 1.37 (1.09, 1.73) 0.007 1.24 (0.99, 1.56) 0.061
Cer(d18:1/18:0) 1.34 (1.10, 1.64) 0.004 1.15 (0.92, 1.43) 0.221 1.02 (0.82, 1.28) 0.848
Cer(d18:1/18:0)/Cer(d18:1/24:0) 1.48 (1.21, 1.81) 1.4 × 10−4 1.29 (1.03, 1.61) 0.027 1.24 (1.00, 1.55) 0.053
Cer(d18:1/18:0)/Cer(d18:1/24:1) 1.15 (0.93, 1.40) 0.192 1.02 (0.82, 1.26) 0.862 0.95 (0.77, 1.17) 0.612
HRs are expressed per 1 SD
HbA1c<47.5 mmol/mol (<6.5%)
aUnadjusted models, stratified by vitamin B intervention groups
bModels were stratified by vitamin B intervention group and adjusted for age at baseline, sex, BMI, HDL-C, CRP, systolic blood pressure, lipid-lowering
treatment and current smoking
cModels were additionally adjusted for fasting glucose and HbA1c
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age, sex and BMI, the variables selected for these models were
those that showed significant HRs (ESM Table 4) and were
available for all participants in the FINRISK 2002 study.
Furthermore, in FINRISK 2002 we compared the results with
Table 3 Performance of predictive models for incident diabetes
Variable FINRISK 2002 WECAC
C-statistic HL p value Δ C-statistic Δ p value C-statistic HL p value Δ C-statistic Δ p value
Age + BMI + sex + T2D risk
factorsa + ceramide ratio
0.828 0.152 0.011 0.001 – – – –
Age + BMI + sex + T2D risk factorsa 0.817 0.059 – – – –
Age + BMI + sex + TG + ceramide ratio 0.824 0.381 0.012 4.1 × 10−4 0.736 0.074 0.020 0.035
Age + BMI + sex + TG 0.812 0.210 0.716 0.679
Age + BMI + sex + HDL-C +
ceramide ratio
0.813 0.482 0.014 0.001 0.731 0.203 0.027 0.016
Age + BMI + sex + HDL-C 0.799 0.042 0.705 0.819
Age + BMI + sex + CRP + ceramide ratio 0.813 0.157 0.014 0.001 0.719 0.066 0.028 0.018
Age + BMI + sex + CRP 0.799 0.001 0.691 0.161
Age + BMI + sex + systolic BP +
ceramide ratio
0.812 0.111 0.017 6.0 × 10−5 0.708 0.426 0.034 0.003
Age + BMI + sex + systolic BP 0.796 0.204 0.674 0.114
Age + BMI + sex + ceramide ratio 0.810 0.159 0.017 1.3 × 10−4 0.712 0.175 0.031 0.012
Age + BMI + sex 0.794 0.090 0.681 0.242
Age + sex + ceramide ratio 0.763 0.003 0.083 1.3 × 10−16 0.652 0.046 0.130 5.7 × 10−7
Age + sex 0.680 0.016 0.522 0.002
In FINRISK 2002, the models were cross-validated ten times. In addition to C-statistics, the table shows Hosmer–Lemeshow (HL) test p values for
model calibration, and the difference between C-statistics, together with p values for models with and without the Cer(d18:1/18:0)/Cer(d18:1/16:0)
ceramide ratio. The coefficients derived in FINRISK 2002 for 10 year risk were applied toWECAC, while the baseline hazard for 7 years was used in the
WECAC models
a T2D (type 2 diabetes) risk factors were family history, physical activity, waist circumference and systolic blood pressure with 15 mmHg added for
participants on antihypertensive medication
Table 4 Mean risk for incident diabetes, with individuals categorised based on predicted risk
dScore Value FINRISK WECAC WECAC (HbA1c
< 47.5 mmol/mol)
Interpretation
Population (%) Risk (%) Population (%) Risk (%) Population (%) Risk (%)
1 Ceramide ratio + BMI + sex + age 0–5 61.3 1.5 51.6 2.4 64.0 2.0 Low risk
5–15 28.8 9.1 41.0 8.1 32.4 8.3 Moderate risk
15+ 9.9 24.2 7.4 16.9 3.6 13.8 High risk
2 Ceramide ratio + BMI + TG+ sex + age 0–5 62.6 1.5 48.5 1.7 59.7 2.0 Low risk
5–15 26.6 8.5 40.0 7.6 33.7 6.9 Moderate risk
15+ 10.8 25.4 11.4 16.9 6.6 15.0 High risk
Cox regression risk score formulas in FINRISK 2002 were derived as previously described [30]
dScore1, men: 1−0:9670e
1:5140loge ageð Þþ4:1844loge BMIð Þþ1:8891loge Cer d18:1=18:0ð Þ=Cer d18:1=16:0ð Þð Þ−17:4695
h i
100
dScore1, women: 1−0:9670e
1:5140loge ageð Þþ4:1844loge BMIð Þþ1:8891loge Cer d18:1=18:0ð Þ=Cer d18:1=16:0ð Þð Þ−18:0096
h i
100
dScore2, men: 1−0:9693e
1:5094loge ageð Þþ3:6396loge BMIð Þþ0:7680loge TGð Þþ1:6868loge Cer d18:1=18:0ð Þ=Cer d18:1=16:0ð Þð Þ−16:1198
h i
100
dScore2, women: 1−0:9693e
1:5094loge ageð Þþ3:6396loge BMIð Þþ0:7680loge TGð Þþ1:6868loge Cer d18:1=18:0ð Þ=Cer d18:1=16:0ð Þð Þ−16:4407
h i
100
Units: age, years; BMI, kg/m2 ; TG, mmol/l; ceramide ratio; no unit
The risk in FINRISK 2002 is for 10 years, and in WECAC is for 7 years. In WECAC, participants who died without incident diabetes before the end of
the follow-up were excluded from calculations to derive this table
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risk factors currently used in diabetes risk scores. In all models,
the addition of Cer(d18:1/18:0)/Cer(d18:1/16:0) statistically
significantly increased the C-statistic in both the FINRISK
2002 and WECAC studies (Table 3). Most of the models also
showed adequate calibration in both studies. In the WECAC
study with an HbA1c cut-off, the C-statistic also showed an
increase but were not statistically significant (ESM Table 7).
The highest C-statistics were obtained when the ceramide ratio
was added on top of age, BMI, sex and TGs (C-statistic 0.824
in FINRISK 2002 and 0.736 in WECAC) or traditional risk
factors (C-statistic 0.828 in FINRISK) (Table 3). These two
models had equally good predictive value in FINRISK 2002
(p = 0.40 for the difference in C-statistics).
Two diabetes scores (dScores) were constructed for
Cer(d18:1/18:0)/Cer(d18:1/16:0) that could be used to predict
the onset of diabetes, using also BMI and age with or without
TG. For scoring, the regression models developed in the
FINRISK 2002 for the 10 year risk were used, and individuals
were divided into three groups based on the predicted risk. For
both scores in FINRISK 2002, approximately 60% of the
population had a low risk of 1.5% for developing incident
diabetes in 10 years, whereas for the individuals in the high
risk group the risk was on average 25%, i.e. 17-fold the low-
risk group (Table 4). The scores were validated in the
WECAC cohort, where roughly half of the population
belonged to the low-risk group (2.4% and 1.7% developed
incident diabetes, for dScore1 and dScore2, respectively),
while the highest risk individuals had an average 17% risk
of developing incident diabetes (Table 4).
Weight loss reduces the ceramide ratio The effect of nutri-
tional intervention and resulting weight loss on the ceramide
ratio was investigated in the PrevMetSyn dietary intervention
study (n = 371; ESM Table 8). The ceramide ratio was signif-
icantly reduced in individuals with weight loss of 5% or more,
and the result was more significant after 2 years (Fig. 2, ESM
Fig. 1) than 1 year. Glucose showed a similar trend, whereas
for insulin the changes between participants with either weight
loss or weight gain were stronger. Interestingly, HbA1c and
CRP did not show trends according to change in weight.
The diabetes scores were significantly reduced in individuals
with a weight loss of 2% or more.
Discussion
In this study, it has been shown for the first time that the
Cer(d18:1/18:0)/Cer(d18:1/16:0) ratio is an independent
marker for risk of incident diabetes. Moreover, this ratio was
decreased in individuals with a weight loss of 5% or more,
which is in line with dietary intervention studies showing that
even a weight loss of a few kilograms is sufficient to lower the
risk of developing diabetes [19]. New diabetes scores have
been proposed to improve the prediction of incident diabetes.
These d18:1 ceramides have been extensively investigated
in plasma, skeletal muscle, liver and adipose tissue in human
and animal studies, but this is the first study to show that the
Cer(d18:1/18:0)/Cer(d18:1/16:0) ratio stands out as a superior
ceramide biomarker for the onset of incident diabetes. This
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Fig. 2 Change in ceramide ratio and other variables in individuals with
different weight changes, resulting from dietary intervention, after (a) 1 or
(b) 2 years. The bars represent the mean relative change (%) between time
points. Black bars, weight loss >5%; white bars, weight loss 2–5%; light
grey bars, weight loss 0–2%; dark grey bars, weight gain 0–2%; horizon-
tally hatched bars, weight gain >2%. *p < 0.05, **p < 0.01, ***p < 0.001.
Individual data points are shown in ESM Fig. 1. The calculations for
dScores are presented in Table 4
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raises the question of why this ratio in particular offers the best
predictive ability. One answer comes from our analyses show-
ing that among the ceramides Cer(d18:1/18:0) was the most,
and Cer(d18:1/16:0) the least, significantly correlated cer-
amide with BMI, fasting glucose, insulin and HbA1c, which
are all important factors predisposing an individual to the on-
set of diabetes. Thus, the very different associations of these
two ceramides with the development of insulin resistance may
explain the predictive power of this ratio. However,
Cer(d18:1/18:0)/Cer(d18:1/16:0) also predicts incident diabe-
tes independently of glucose and HbA1c.
The important role of Cer(d18:1/18:0) in the development of
insulin resistance has been demonstrated in several studies. In
the Australian Diabetes, Obesity and Lifestyle Study (AusDiab),
both plasma Cer(d18:1/18:0) and its precursor Cer(d18:0/18:0)
showed strong associations with type 2 diabetes and prediabetes
[20]. It has been documented in another human study that insu-
lin sensitivity inversely correlates especially with plasma
Cer(d18:1/18:0) [21], and this was also the most upregulated
ceramide in plasma in genetically obese (ob/ob) mice [22].
Insulin resistance in skeletal muscle plays a major role in
the development of type 2 diabetes [23], and there are mixed
results for the Cer(d18:1/18:0) and Cer(d18:1/16:0) ceramides
in the literature, although most studies support the importance
of Cer(d18:1/18:0) in the development of insulin resistance in
muscle. In a study investigating insulin resistance in humans,
it was shown that, in muscle, Cer(d18:1/18:0) was the only
lipid elevated by insulin resistance independently of obesity,
and in plasma, Cer(d18:1/18:0), together with its precursor
Cer(d18:0/18:0), was associated with both insulin resistance
and obesity [24]. The same study also demonstrated that there
was a positive correlation between plasma and muscle con-
centrations of Cer(d18:1/18:0), and this lipid correlated posi-
tively with visceral and liver fat and inversely with metabolic
flexibility, which was determined by the change in respiratory
quotient at rest and after insulin stimulation [24]. Another
study supports these findings by showing that the concentra-
tion of Cer(d18:1/18:0) was significantly higher in type 2
diabetic individuals than athletes, and it was positively asso-
ciated with BMI and inversely associated with insulin sensi-
tivity [25]. However, there is a study demonstrating that
Cer(d18:1/16:0) is more strongly increased than Cer(d18:1/
18:0) in the muscle of obese individuals [26].
The results in adipose tissue are more controversial than
those observed in muscle. Elevated expression of ceramide
synthase 6, responsible for the synthesis of Cer(d18:1/16:0),
has been demonstrated in adipose tissue in obese humans,
together with increased concentrations of Cer(d18:1/16:0)
and Cer(d18:1/18:0) [27]. CerS6-deficient mice, and also
models with specific knockout in brown adipose tissue and
liver, are protected from diet-induced obesity and glucose in-
tolerance [27]. However, contradictory results were obtained
in another study showing that obesity leads to the degradation
of ceramides in the adipose tissue of obese (ob/ob) mice [22].
The accumulation of ceramides in adipose tissue in obesity
was again supported by a mouse study which showed that
both Cer(d18:1/16:0) and Cer(d18:1/18:0) were already ele-
vated in adipose tissue after 1 week on a high-fat diet [28]. In
this study, it was also reported that the high-fat diet induced in
particular an elevation of Cer(d18:1/18:0) in muscle, and in
liver Cer(d18:1/18:0) was elevated after 16 weeks, but not as
much as Cer(d18:1/20:0) or Cer(d18:1/22:0) [28].
Taken together, these studies suggest that the observed in-
crease of especially Cer(d18:1/18:0) in obese and insulin-
resistant individuals is a result of the regulation and synthesis
of ceramides in several different organs. Numerous studies
have investigated the mechanisms by which ceramides affect
insulin sensitivity, and there are several pathways that induce
ceramide synthesis, such as saturated fatty acids and activation
of inflammatory pathways triggered by Toll-like receptor 4
(TLR4) recognition of the saturated fatty acids [4].
Furthermore, the insulin sensitiser adiponectin and endoplas-
mic reticulum stress modulate ceramide metabolism [4]. The
accumulated ceramides then inhibit insulin signalling by de-
creasing the activity of Akt (also known as protein kinase B)
via protein phosphatase 2A or atypical protein kinase C [5].
However, further studies are needed to understand why stearic
acid-containing ceramides in particular are strongly associated
with the development of obesity and insulin resistance.
The strength of our study was that the results were derived
from a large population-based study and validated in another
large cohort of individuals with suspected stable angina
pectoris, and both studies had long follow-up times. Despite
the apparent differences between these studies, the results
were consistent, which supports the robustness of our obser-
vations. Another strength was that, using the ceramide ratio
and other laboratory measurements, we were able to obtain a
better prediction than with the traditional risk factors, such as
BMI, physical activity and family history of diabetes.
However, a limitation of our study was that we did not have
available all the risk factors of the current diabetes risk calcu-
lators, such as history of blood glucose levels, gestational
diabetes and blood pressure medication, or nutritional data,
and therefore we could not compare the developed models
explicitly with current risk calculators. However, it is notewor-
thy that the ceramide ratio also improved the model consisting
of several established risk factors, including BMI, waist cir-
cumference, family history, blood pressure and physical activ-
ity. Another limitation was the slight difference in the follow-
up times of the two cohorts, and that the study participants
were not fasting, which may especially affect TG levels.
It has recently been suggested that the investigated
ceramides should be adopted into clinical practice for cardio-
vascular risk prediction [29], and it is therefore a tempting idea
that the same molecules, although in a different ratio, could
also be used to predict risk of diabetes. An interesting topic for
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further investigation is whether these ceramides could predict
the cardiovascular complications of diabetes. Another inter-
esting area for study is the predictive value of the Cer(d18:1/
18:0)/Cer(d18:1/16:0) ratio for gestational diabetes, and, as
the ceramide ratio was elevated in individuals on statin treat-
ment, to explore whether this ratio could serve as a biomarker
for statin-induced diabetes.
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